Drug Registration in Malaysia: Process, Timeline and Requirements (2026)

Q: What is the fastest way to register an FDA- or EMA-approved drug in Malaysia?

The fast-track recognition route, a one-year FRP pilot from 2 May 2026, which targets about 60 working days for products that meet its strict sameness conditions and are filed within three months of the reference approval.

Short answer

To sell a medicine in Malaysia it must be registered with the regulator, NPRA, under the Control of Drugs and Cosmetics Regulations 1984. A foreign manufacturer cannot hold that registration directly: a locally incorporated Marketing Authorisation Holder (MAH) submits the dossier and holds the licence on your behalf. How long it takes depends on the route - a full evaluation is the longest, reliance routes are faster, and since 2 May 2026 an FDA- or EMA-approved product can qualify for a fast-track target of about 60 working days. This guide covers who can register, the routes and timelines, what the dossier needs, and the practical steps.

"How do I register a drug in Malaysia, how long does it take, and what does it cost?" is the question every foreign manufacturer asks first - and the honest answer has always been "it depends." This guide makes the dependencies explicit: the steps are the same for everyone, but the route you qualify for changes the timeline dramatically, and a few structural decisions - chiefly, who holds the registration - shape the rest.

Who can hold a drug registration in Malaysia

Medicines in Malaysia are regulated by the National Pharmaceutical Regulatory Agency (NPRA) under the Control of Drugs and Cosmetics Regulations 1984 (CDCR 1984), made under the Sale of Drugs Act 1952. No product may be sold, supplied or imported unless it is a registered product and the responsible party holds the appropriate licence.

The key structural rule: a foreign manufacturer cannot hold its own registration. The registration is held by a locally incorporated Marketing Authorisation Holder (MAH) - a Malaysian legal entity registered with the Companies Commission of Malaysia (SSM). The MAH submits the application, is the party NPRA corresponds with, and holds the product licence on the manufacturer's behalf. The product itself is identified by a registration number (MAL number) once approved.

Applications are filed through NPRA's online product registration system, QUEST3+. Because the MAH controls the submission account and the licence, who you appoint as MAH is a decision with long-term consequences (see our guide on keeping control of your registration).

The registration routes and how long each takes

Malaysia does not have a single timeline. NPRA offers a full evaluation plus several reliance routes that lean on prior approvals by trusted "reference" regulators. Timelines depend on product category and route, and are administrative targets - they exclude screening time and any time the file spends with you answering NPRA's questions.

Full evaluation - the standard route for products that require a full local review; the timeline depends on product category.
Reliance routes under the Facilitated Registration Pathway (FRP) - abbreviated review (for a product already approved by one recognised reference agency) or verification review (two reference agencies, or via the ASEAN Joint Assessment procedure).
Fast-track recognition route - a one-year FRP pilot from 2 May 2026 for a product already approved by the US FDA or EMA, under strict "sameness" conditions and a filing window of three months from the reference approval, with NPRA aiming to process a qualifying application in about 60 working days from payment after screening.

The recognition route is the newest and most relevant for many foreign manufacturers: it lets NPRA rely on an existing US FDA or EMA approval, with strict conditions (an identical dossier, manufacturing sites and Risk Management Plan; submission within three months of the reference approval). The full mechanics are in our guide to fast-track drug registration in Malaysia.

What you need to register a drug

A locally incorporated MAH to submit and hold the registration, authorised in writing by the intellectual-property (IP) product owner through a Letter of Authorisation.
A registration dossier in NPRA's required format. Standard routes follow the ASEAN Common Technical Dossier / Requirements (ACTD / ACTR) - quality, safety and efficacy documentation. Under the fast-track recognition route the submission instead relies on your approved FDA/EMA dossier, with Malaysia-specific additions (labelling, climate-appropriate stability data and the Risk Management Plan).
GMP evidence. Malaysia is a PIC/S member, so Good Manufacturing Practice (GMP) documentation from EU/PIC/S manufacturers generally fits NPRA's expectations, with the exact documents depending on the foreign site and product category.
Stability data suited to Malaysia's climate (ASEAN Climate Zone IVb). Under the recognition route, NPRA expects a minimum of 12 months real-time and 6 months accelerated stability data, where applicable; requirements for other routes should be checked by product category.
Malaysia-compliant labelling and product information (package insert / consumer leaflet).

The registration process, step by step

Assess the route. Determine whether your product qualifies for a reliance route (abbreviated or verification) or the fast-track recognition route. An existing FDA/EMA approval usually opens the fastest options.
Appoint a Malaysian MAH. This is a legal requirement, not an option, and it decides who controls your licence.
Prepare the dossier to the current DRGD (3rd Edition, 12th Revision, July 2026), including GMP evidence and climate-appropriate stability data.
Submit via QUEST3+, pay, and manage correspondence. For reliance routes the administrative clock starts after screening and payment; correspondence rounds are limited, so a clean submission protects the timeline.
Receive the registration number (MAL number) and maintain the registration - variations, renewals and, where relevant, additional indications are managed through the MAH.

How long and how much, realistically

The headline numbers are administrative targets, not end-to-end timelines. For the 2026 fast-track recognition pilot, NPRA aims to process qualifying FDA/EMA-based applications in about 60 working days from payment after screening; other route timelines depend on product category and the applicable NPRA pathway. Real elapsed time also includes preparing the dossier, screening and any correspondence rounds, so plan in months rather than days, especially for a first submission.

Fees vary by product category and route and are set out in the DRGD fee schedule, so current amounts should be checked against the latest NPRA guidance before budgeting. A change of MAH is a separate post-approval transfer procedure: NPRA charges a non-refundable processing fee of RM 1,000 for a pharmaceutical product and aims to process the application within 45 working days once it is complete.

How RHMI helps Appointing your commercial distributor as the MAH is the common - and risky - default: it hands the company that sells your product legal control of your registration. RHMI acts as your locally incorporated Marketing Authorisation Holder: we choose the fastest route your product qualifies for, prepare and file the dossier to the current DRGD via QUEST3+, manage the limited NPRA correspondence, and maintain the registration (variations, renewals, pharmacovigilance) afterwards - and can grow into your import and distribution partner. The safeguard is contractual and agreed up front: dossier and data ownership, guaranteed transfer rights, and a clear exit, so the registration remains your asset.

In one line

Registration in Malaysia is a defined process - MAH → dossier via QUEST3+ → route-based evaluation → MAL number - where the route you qualify for, not the paperwork, decides whether the timeline is weeks or the better part of a year.

Frequently asked questions

Can a foreign company register a drug in Malaysia itself?

No. A foreign manufacturer cannot hold a Malaysian registration directly. A locally incorporated Marketing Authorisation Holder (MAH) must submit and hold the licence on your behalf, authorised by the IP product owner through a Letter of Authorisation.

How long does drug registration in Malaysia take?

It depends on the route and product category. For the 2026 fast-track recognition pilot, NPRA aims to process qualifying FDA/EMA-based applications in about 60 working days from payment after screening. Full evaluation takes longer, and other reliance-route timelines depend on the applicable NPRA pathway. These timelines exclude screening and applicant response time, so plan in months end to end.

What is the fastest way to register an FDA- or EMA-approved drug?

The fast-track recognition route (a one-year FRP pilot from 2 May 2026), which targets about 60 working days for products that meet its strict "sameness" conditions and are filed within three months of the reference approval.

What documents are required?

A registration dossier in NPRA's required format (the ASEAN Common Technical Dossier for standard routes, or the approved FDA/EMA dossier with Malaysia-specific additions under the recognition route), GMP evidence (Malaysia is PIC/S), climate-appropriate stability data, Malaysia-compliant labelling, and a local MAH authorised by the IP product owner. The exact set depends on the route and product category under the current DRGD.

You might also find useful

Sources (primary):
NPRA - Drug Registration Guidance Document (DRGD, 3rd Edition, 12th Revision, July 2026): npra.gov.my (DRGD)
NPRA - Change of Product Registration Holder (COH): npra.gov.my (COH)
NPRA - Facilitated Registration Pathway / recognition pilot (2 May 2026): npra.gov.my (FRP)
Control of Drugs and Cosmetics Regulations 1984: pharmacy.moh.gov.my
Editorial note: This article is general business and regulatory information for manufacturers evaluating Malaysia. It is not legal or regulatory advice. Timelines are administrative targets, not guarantees; confirm current routes, DRGD revisions, fees and documentation against NPRA's official guidance before acting.